goKDIGO Profile Banner
KDIGO Profile
KDIGO

@goKDIGO

Followers
38K
Following
3K
Media
706
Statuses
3K

KDIGO is a global non-profit foundation dedicated to improving the care and outcomes of people with kidney disease worldwide.

Joined October 2012
Don't wanna be here? Send us removal request.
@goKDIGO
KDIGO
11 days
Check out the August issue of KDIGO Direct for the latest news from KDIGO: In this issue:.- KDIGO and @ERAkidney sign a new MoU. - KDIGO #APOL1 Kidney Disease Conference Report published in @Kidney_Int . - Take the KDIGO Global Guideline Survey:
Tweet media one
1
3
12
@goKDIGO
KDIGO
11 days
RT @NDTsocial: KDIGO 2025 ADPKD Guideline: . A commentary on diagnosis and management of hepatopancreatic manifestations by the ERA Working….
0
28
0
@goKDIGO
KDIGO
16 days
KDIGO is pleased to share the publication of the APOL1 Kidney Disease Controversies Conference Report in Kidney International. Co-chaired by Akinlolu Ojo, MD (United States) and Ifeoma Ulasi, MD (Nigeria), the Accra, Ghana conference brought together scientists, clinicians, and
Tweet media one
Tweet media two
3
35
114
@goKDIGO
KDIGO
16 days
RT @arkanalabs: A sample from the pathology teaching slide set on Infection Related Glomerulonephritis, jointly prepared by Arkana Laborato….
0
5
0
@goKDIGO
KDIGO
21 days
RT @arkanalabs: A sample from the pathology teaching slide set on Nephrotic Syndrome in Children, jointly prepared by Arkana Laboratories a….
0
2
0
@goKDIGO
KDIGO
23 days
RT @arkanalabs: A sample from the pathology teaching slide set on Minimal Change Disease in Adults, jointly prepared by Arkana Laboratories….
0
4
0
@goKDIGO
KDIGO
23 days
RT @FranLoachamin: Evaluación de la función renal en el 2024 @goKDIGO
Tweet media one
0
8
0
@goKDIGO
KDIGO
1 month
Do you treat #IgAN? . Check out this free KDIGO-Medlive-NORD #CME-credited webinar about why #proteinuria reduction matters, how #KDIGO guidelines shape care, and what new therapies targeting endothelin-1 and angiotensin-2 mean for your patients:
Tweet media one
0
14
33
@goKDIGO
KDIGO
1 month
RT @RareDiseases: Do you treat #IgANephropathy (#IgAN)? Watch NORD's free, #CME-credited session about why #proteinuria reduction matters,….
0
4
0
@goKDIGO
KDIGO
1 month
RT @SENefrologia: 🆕 #ADPKD latest infographic, now part of the @ISNkidneycare Rare Kidney Diseases Toolkit! 🔗 @goKD….
0
18
0
@goKDIGO
KDIGO
1 month
RT @arkanalabs: A sample from the pathology teaching slide set on Nephrotic Syndrome in Children, jointly prepared by Arkana Laboratories a….
0
3
0
@goKDIGO
KDIGO
1 month
RT @ISNkidneycare: 📣 𝗡𝗘𝗪 𝗧𝗢𝗢𝗟𝗞𝗜𝗧 𝗥𝗘𝗦𝗢𝗨𝗥𝗖𝗘: Get at-a-glance guidance on #ADPKD with our latest infographic, now part of the ISN Rare Kidney….
0
12
0
@goKDIGO
KDIGO
1 month
RT @arkanalabs: A sample from the pathology teaching slide set on Minimal Change Disease in Adults, jointly prepared by Arkana Laboratories….
0
6
0
@goKDIGO
KDIGO
1 month
Check out the new KDIGO Direct for the latest updates from KDIGO:  In this issue:.- KDIGO Launches Early Career Mentorship Program.- CKD Prevention Conference Report Published in Kidney International.- KDIGO Holds B Cell Controversies Conference.- Take the
Tweet media one
1
2
12
@goKDIGO
KDIGO
1 month
The plenary session recordings are now available from the KDIGO Controversies Conference on Therapies Targeting B Cells in Immune‑Mediated Kidney Diseases, recently held in Panama City, Panama. Watch the recordings: The plenary presentations covered a
Tweet media one
0
7
24
@goKDIGO
KDIGO
2 months
Take the KDIGO Global Guideline Survey!. KDIGO is committed to improving outcomes for people with kidney disease, and your insight is essential. The KDIGO Guideline Implementation & Utilization Global Survey aims to understand how clinicians use our guidelines, where they fall
Tweet media one
0
3
17
@goKDIGO
KDIGO
2 months
RT @arkanalabs: A sample from the pathology teaching slide set on IgA Nephropathy, jointly prepared by Arkana Laboratories and @goKDIGO. ht….
0
11
0
@goKDIGO
KDIGO
2 months
RT @edgarvlermamd: Resistant Membranous Nephropathy: Treatment approach from @goKDIGO .#Nephpearls . 👉 https://t.co….
0
45
0